GSK plc (the ' Company ')
Transaction notification
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Emma Walmsley |
|||
| b) |
Position/status |
Chief Executive Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
29 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Diana Conrad |
|||
| b) |
Position/status |
Chief People Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
5 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
James Ford |
|||
| b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
11 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Sally Jackson |
|||
| b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
19 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Luke Miels |
|||
| b) |
Position/status |
Chief Commercial Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
3 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
David Redfern |
|||
| b) |
Position/status |
President Corporate Development |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
76 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Regis Simard |
|||
| b) |
Position/status |
President, Global Supply Chain |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
29 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Philip Thomson |
|||
| b) |
Position/status |
President, Global Affairs |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
48 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Deborah Waterhouse |
|||
| b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
62 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Victoria Whyte |
|||
| b) |
Position/status |
SVP & Company Secretary |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.3921 |
58 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Sally Jackson |
|||
| b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£ 16.4016 |
1 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Victoria Whyte |
|||
| b) |
Position/status |
SVP & Company Secretary |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£ 16.4016 |
123 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Iain Whyte |
|||
| b) |
Position/status |
PCA of Ms V Whyte (SVP & Company Secretary) |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£ 16.4016 |
1,152 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Emma Walmsley |
|||
| b) |
Position/status |
Chief Executive Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
105.836 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Diana Conrad |
|||
| b) |
Position/status |
Chief People Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
1,233.149 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
James Ford |
|||
| b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
1,024.598
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Sally Jackson |
|||
| b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
453.008
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dylan Jackson |
|||
| b) |
Position/status |
PCA of Sally Jackson ( SVP, Global Communications and CEO Office) |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
140.210
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
David Redfern |
|||
| b) |
Position/status |
President Corporate Development |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
6,278.135
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Regis Simard |
|||
| b) |
Position/status |
President, Global Supply Chain |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
2,616.351
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Philip Thomson |
|||
| b) |
Position/status |
President, Global Affairs |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
2,144.723
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Kate Thomson |
|||
| b) |
Position/status |
PCA of Philip Thomson (President, Global Affairs) |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
109.382
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Deborah Waterhouse |
|||
| b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
1,279.528
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Tony Wood |
|||
| b) |
Position/status |
Chief Scientific Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£16.4016 |
1,270.306
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Victoria Whyte |
|||
| b) |
Position/status |
SVP & Company Secretary |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 |
|||
| b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025. |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
£ 16.4016 |
1.332
|
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-09 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Elizabeth McKee Anderson |
|||
| b) |
Position/status |
Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
26 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Charles Bancroft |
|||
| b) |
Position/status |
Senior Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
340 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Hal Barron |
|||
| b) |
Position/status |
Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
28 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Anne Beal |
|||
| b) |
Position/status |
Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
34 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Harry Dietz |
|||
| b) |
Position/status |
Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
32 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Jeannie Lee |
|||
| b) |
Position/status |
Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
13 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr Vishal Sikka |
|||
| b) |
Position/status |
Independent Non-Executive Director |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GSK plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025 |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
| |
$43.7375 |
99 |
|
||
| |
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
| Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2025-10-10 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.